Displaying drugs 14451 - 14475 of 15470 in total
Propionibacterium acnes
Investigational
Lactobacillus crispatus strain CTV-05
Investigational
Tivanisiran
Tivanisiran is under investigation in clinical trial NCT03108664 (HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)).
Investigational
Lapuleucel-t
Investigational
Redasemtide
Redasemtide is under investigation in clinical trial NCT05953480 (A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke).
Investigational
Baltaleucel-T
Investigational
EMI-137
EMI-137 is under investigation in clinical trial NCT03360461 (EMI-137 in Laparoscopic Colonic Resections).
Investigational
Onvitrelin ucalontide
Onvitrelin ucalontide is under investigation in clinical trial NCT01485848 (EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer).
Investigational
Atexakin alfa
Atexakin alfa is under investigation in clinical trial NCT05435742 (SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)).
Investigational
Lixudebart
Lixudebart, an investigational first-in-class monoclonal antibody, aims to reverse fibrosis.
Investigational
Bos taurus colostrum
Investigational
Ecklonia cava
Investigational
Stapuldencel
Investigational
Pseudomonas aeruginosa
Investigational
Cancer/testis antigen 1
Investigational
Human placenta hydrolysate
Investigational
Interleukin-12 human recombinant
Investigational
Bemiltenase alfa
Investigational
RTL-1000
RTL-1000 is a recombinant T-Cell receptor ligand being investigated for the treatment of multiple sclerosis.
Investigational
TG4023
Investigational
N-[3-(aminomethyl)benzyl]acetamidine
Experimental
Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone
Experimental
CX157
CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
Investigational
Matched Description: … dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and …
Ulixertinib
Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity . It is currently in clinical trials for the treatment of a wide range of tumors.
Investigational
Matched Description: … Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity …
Serabelisib
Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).
Investigational
Matched Description: … investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and …
Displaying drugs 14451 - 14475 of 15470 in total